PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $0 | Sep 30, 2025 |
| FY2025 | May 31, 2024 | $0 | Sep 30, 2025 |
| FY2024 | May 31, 2023 | $0 | Oct 10, 2024 |
| FY2023 | May 31, 2022 | $368 | Aug 30, 2023 |
| FY2022 | May 31, 2021 | $411 | Sep 29, 2022 |
| FY2021 | May 31, 2020 | $0 | Sep 9, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | May 31, 2023 | $0 | Aug 30, 2023 |
| FY2023 | May 31, 2022 | $368 | Aug 30, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($82.0K) | Sep 30, 2025 |
| FY2025 | May 31, 2024 | ($99.4K) | Sep 30, 2025 |
| FY2024 | May 31, 2023 | ($156.3K) | Oct 10, 2024 |
| FY2023 | May 31, 2022 | ($180.6K) | Aug 30, 2023 |
| FY2022 | May 31, 2021 | ($163.2K) | Sep 29, 2022 |
| FY2021 | May 31, 2020 | ($171.7K) | Sep 9, 2021 |
| FY2019 | May 31, 2019 | ($197.8K) | Sep 14, 2020 |
| FY2019 | May 31, 2018 | ($201.7K) | Aug 27, 2019 |
| FY2018 | May 31, 2017 | ($262.0K) | Sep 13, 2018 |
| FY2017 | May 31, 2016 | ($265.6K) | Aug 30, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($152.1K) | Sep 30, 2025 |
| FY2025 | May 31, 2024 | ($99.4K) | Sep 30, 2025 |
| FY2024 | May 31, 2023 | ($156.3K) | Oct 10, 2024 |
| FY2023 | May 31, 2022 | ($180.6K) | Aug 30, 2023 |
| FY2022 | May 31, 2021 | ($163.2K) | Sep 29, 2022 |
| FY2021 | May 31, 2020 | ($171.7K) | Sep 9, 2021 |
| FY2019 | May 31, 2019 | ($197.8K) | Sep 14, 2020 |
| FY2019 | May 31, 2018 | ($201.7K) | Aug 27, 2019 |
| FY2018 | May 31, 2017 | ($249.4K) | Sep 13, 2018 |
| FY2017 | May 31, 2016 | ($234.7K) | Aug 30, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $0 | Sep 30, 2025 |
| FY2025 | May 31, 2024 | $5.6K | Sep 30, 2025 |
| FY2024 | May 31, 2023 | $6.5K | Oct 10, 2024 |
| FY2023 | May 31, 2022 | $25.6K | Aug 30, 2023 |
| FY2022 | May 31, 2021 | $8.2K | Sep 29, 2022 |
| FY2021 | May 31, 2020 | $11.6K | Sep 9, 2021 |
| FY2019 | May 31, 2019 | $26.9K | Sep 14, 2020 |
| FY2019 | May 31, 2018 | $38.1K | Aug 27, 2019 |
| FY2018 | May 31, 2017 | $54.7K | Sep 13, 2018 |
| FY2017 | May 31, 2016 | $31.6K | Aug 30, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($41.5K) | Sep 30, 2025 |
| FY2025 | May 31, 2024 | ($30.9K) | Sep 30, 2025 |
| FY2024 | May 31, 2023 | ($37.6K) | Oct 10, 2024 |
| FY2023 | May 31, 2022 | ($64.0K) | Aug 30, 2023 |
| FY2022 | May 31, 2021 | ($35.7K) | Sep 29, 2022 |
| FY2021 | May 31, 2020 | ($30.6K) | Sep 9, 2021 |
| FY2019 | May 31, 2019 | ($86.2K) | Sep 14, 2020 |
| FY2019 | May 31, 2018 | ($71.0K) | Aug 27, 2019 |
| FY2018 | May 31, 2017 | ($118.4K) | Sep 13, 2018 |
| FY2017 | May 31, 2016 | ($54.7K) | Aug 30, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $0 | Sep 30, 2025 |
| FY2025 | May 31, 2024 | $14 | Sep 30, 2025 |
| FY2024 | May 31, 2023 | $6 | Oct 10, 2024 |
| FY2023 | May 31, 2022 | $259 | Aug 30, 2023 |
| FY2022 | May 31, 2021 | $40 | Sep 29, 2022 |
| FY2021 | May 31, 2020 | $46 | Sep 9, 2021 |
| FY2019 | May 31, 2019 | $17.9K | Sep 14, 2020 |
| FY2019 | May 31, 2018 | $7.6K | Aug 27, 2019 |
| FY2018 | May 31, 2017 | $8.8K | Sep 13, 2018 |
| FY2017 | May 31, 2016 | $41.2K | Aug 30, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $2.34M | Sep 30, 2025 |
| FY2025 | May 31, 2024 | $2.40M | Sep 30, 2025 |
| FY2024 | May 31, 2023 | $2.30M | Oct 10, 2024 |
| FY2023 | May 31, 2022 | $2.14M | Aug 30, 2023 |
| FY2022 | May 31, 2021 | $1.96M | Sep 29, 2022 |
| FY2021 | May 31, 2020 | $1.80M | Sep 9, 2021 |
| FY2019 | May 31, 2019 | $1.69M | Sep 14, 2020 |
| FY2019 | May 31, 2018 | $1.53M | Aug 27, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($2.34M) | Sep 30, 2025 |
| FY2025 | May 31, 2024 | ($2.40M) | Sep 30, 2025 |
| FY2025 | May 31, 2023 | ($2.30M) | Sep 30, 2025 |
| FY2024 | May 31, 2022 | ($2.14M) | Oct 10, 2024 |
| FY2023 | May 31, 2021 | ($1.96M) | Aug 30, 2023 |
| FY2022 | May 31, 2020 | ($1.80M) | Sep 29, 2022 |
| FY2021 | May 31, 2019 | ($1.67M) | Sep 9, 2021 |
| FY2019 | May 31, 2018 | ($1.53M) | Sep 14, 2020 |
| FY2019 | May 31, 2017 | ($1.33M) | Sep 14, 2020 |
| FY2018 | May 31, 2016 | ($1.63M) | Sep 13, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($5.21M) | Sep 30, 2025 |
| FY2025 | May 31, 2024 | ($5.13M) | Sep 30, 2025 |
| FY2024 | May 31, 2023 | ($5.03M) | Oct 10, 2024 |
| FY2023 | May 31, 2022 | ($4.87M) | Aug 30, 2023 |
| FY2022 | May 31, 2021 | ($4.69M) | Sep 29, 2022 |
| FY2021 | May 31, 2020 | ($4.53M) | Sep 9, 2021 |
| FY2019 | May 31, 2019 | ($4.36M) | Sep 14, 2020 |
| FY2019 | May 31, 2018 | ($4.16M) | Aug 27, 2019 |
| FY2018 | May 31, 2017 | ($3.96M) | Sep 13, 2018 |
| FY2017 | May 31, 2016 | ($3.70M) | Aug 30, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $0 | Sep 30, 2025 |
| FY2025 | May 31, 2024 | $14 | Sep 30, 2025 |
| FY2024 | May 31, 2023 | $6 | Oct 10, 2024 |
| FY2023 | May 31, 2022 | $259 | Aug 30, 2023 |
| FY2022 | May 31, 2021 | $40 | Sep 29, 2022 |
| FY2021 | May 31, 2020 | $46 | Sep 9, 2021 |
| FY2021 | May 31, 2019 | $17.9K | Sep 9, 2021 |
| FY2019 | May 31, 2018 | $7.6K | Aug 27, 2019 |
| FY2019 | May 31, 2017 | $8.8K | Sep 14, 2020 |
| FY2018 | May 31, 2016 | $7.2K | Sep 13, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | 0 | Sep 30, 2025 |
| FY2025 | May 31, 2024 | 0 | Sep 30, 2025 |
| FY2024 | May 31, 2023 | 0 | Oct 10, 2024 |
| FY2023 | May 31, 2022 | 0 | Aug 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | 0 | Sep 30, 2025 |
| FY2025 | May 31, 2024 | 0 | Sep 30, 2025 |
| FY2024 | May 31, 2023 | 0 | Oct 10, 2024 |
| FY2023 | May 31, 2022 | 0 | Aug 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | 19.77M | Sep 30, 2025 |
| FY2025 | May 31, 2024 | 19.77M | Sep 30, 2025 |
| FY2024 | May 31, 2023 | 19.77M | Oct 10, 2024 |
| FY2023 | May 31, 2022 | 19.77M | Aug 30, 2023 |
| FY2022 | May 31, 2021 | 19.77M | Sep 29, 2022 |
| FY2021 | May 31, 2020 | 19.77M | Sep 9, 2021 |
| FY2019 | May 31, 2019 | 19.67M | Sep 14, 2020 |
| FY2019 | May 31, 2018 | 19.57M | Aug 27, 2019 |